Int J Sports Med 2013; 34(01): 74-80
DOI: 10.1055/s-0032-1316319
Clinical Sciences
© Georg Thieme Verlag KG Stuttgart · New York

Platelet Function and Constituents of Platelet Rich Plasma

M. H. Pelletier
1   Surgical & Orthopaedic Research Labs, University of New South Wales, Randwick, Australia
A. Malhotra
1   Surgical & Orthopaedic Research Labs, University of New South Wales, Randwick, Australia
T. Brighton
2   Department of Haematology, Prince of Wales Hospital, Randwick, Australia
W. R. Walsh
1   Surgical & Orthopaedic Research Labs, University of New South Wales, Randwick, Australia
R. Lindeman
2   Department of Haematology, Prince of Wales Hospital, Randwick, Australia
› Author Affiliations
Further Information

Publication History

accepted after revision 10 May 2012

Publication Date:
14 August 2012 (online)


Platelet Rich Plasma (PRP) therapies require blood to be processed prior to application, however, the full assessment of the output of platelet sequestration devices is lacking. In this study the products of the Autologous Fluid Concentrator (Circle BiologicsTM, Minneapolis, MN) and the Gravitational Platelet Separation System (GPS, Biomet, Warsaw, IN, USA) were evaluated in terms of platelet viability and PRP constituents. The AFC and GPS produced 6.4 (±1.0) ml and 6.3 (±0.4) ml of PRP, with platelet recovery of 46.4% (±14.7%) and 59.8% (±24.2%) producing fold increases of platelets of 4.19 (±1.62) and 5.19 (±1.62), respectively. Fibrinogen concentration was increased above baseline PPP produced with the AFC. pH was lower for both of the processed samples than for whole blood. White Blood Cell count was increased around 5 fold. Functional tests showed preserved viability with both devices. This represents essential knowledge that every treating physician should have before they can confidently administer PRP therapy produced by any method. These are the first published results of platelet function for the GPS system and the first performance results of the AFC system. The PRP produced is classified according to broad classifications as Leukocyte-PRP (L-PRP) for both devices.

  • References

  • 1 Alsousou J, Thompson M, Hulley P, Noble A, Willett K. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br 2009; 91: 987-996
  • 2 Anitua E, Sanchez M, Orive G, Andia I. Shedding light in the controversial terminology for platelet rich products. J Biomed Mater Res A 2009; 90: 1262-1263
  • 3 Arora NS, Ramanayake T, Ren YF, Romanos GE. Platelet-rich plasma: a literature review. Implant Dent 2009; 18: 303-310
  • 4 Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 2009; 23: 177-189
  • 5 Borrione P, Gianfrancesco AD, Pereira MT, Pigozzi F. Platelet-rich plasma in muscle healing. Am J Phys Med Rehabil 2010; 89: 854-861
  • 6 Cervelli V, Gentile P, Scioli MG, Grimaldi M, Casciani CU, Spagnoli LG, Orlandi A. Application of platelet-rich plasma in plastic surgery: clinical and in vitro evaluation. Tissue Eng Part C Methods 2009; 15: 625-634
  • 7 Cieslik-Bielecka A, Gazdzik TS, Bielecki TM, Cieslik T. Why the platelet-rich gel has antimicrobial activity?. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103: 303-305 author reply 305-306
  • 8 Clark RA. Fibrin and wound healing. Ann NY Acad Sci 2001; 936: 355-367
  • 9 de Vos RJ, van Veldhoven PL, Moen MH, Weir A, Tol JL, Maffulli N. Autologous growth factor injections in chronic tendinopathy: a systematic review. Br Med Bull 2010; 95: 63-77
  • 10 Ding XG, Li SW, Zheng XM, Hu LQ, Hu WL, Luo Y. The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. Asian J Androl 2009; 11: 215-221
  • 11 Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol 2009; 27: 158-167
  • 12 Dumont LJ, VandenBroeke T, Ault KA. Platelet surface P-selectin measurements in platelet preparations: an international collaborative study. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT). Transfus Med Rev 1999; 13: 31-42
  • 13 Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004; 114: 1502-1508
  • 14 Everts PA, Brown Mahoney C, Hoffmann JJ, Schonberger JP, Box HA, van Zundert A, Knape JT. Platelet-rich plasma preparation using three devices: implications for platelet activation and platelet growth factor release. Growth Factors 2006; 24: 165-171
  • 15 Everts PA, Hoffmann J, Weibrich G, Mahoney CB, Schonberger JP, van Zundert A, Knape JT. Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation. Transfus Med 2006; 16: 363-368
  • 16 Flad HD, Brandt E. Platelet-derived chemokines: pathophysiology and therapeutic aspects. Cell Mol Life Sci 2010; DOI: 10.1007/s00018-010-0306-x.
  • 17 Gociman B, Agk M, Moran S. Caption: a filtration-based platelet concentration system. Expert Rev Med Devices 2009; 6: 607-610
  • 18 Graff J, Klinkhardt U, Schini-Kerth VB, Harder S, Franz N, Bassus S, Kirchmaier CM. Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor. J Pharmacol Exp Ther 2002; 300: 952-957
  • 19 Grageda E, Lozada JL, Boyne PJ, Caplanis N, McMillan PJ. Bone formation in the maxillary sinus by using platelet-rich plasma: an experimental study in sheep. J Oral Implantol 2005; 31: 2-17
  • 20 Graziani F, Ivanovski S, Cei S, Ducci F, Tonetti M, Gabriele M. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin Oral Implants Res 2006; 17: 212-219
  • 21 Harriss DJ, Atkinson G. Update – ethical standards in sport and exercise science research. Int J Sports Med 2011; 32: 819-821
  • 22 Holme S, Sweeney JD, Sawyer S, Elfath MD. The expression of p-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion 1997; 37: 12-17
  • 23 Kim BK, Baldini MG. The platelet response to hypotonic shock. Its value as an indicator of platelet viability after storage. Transfusion 1974; 14: 130-138
  • 24 Landolfi R, De Cristofaro R, De Candia E, Rocca B, Bizzi B. Effect of fibrinogen concentration on the velocity of platelet aggregation. Blood 1991; 78: 377-381
  • 25 Laurens N, Koolwijk P, de Maat MP. Fibrin structure and wound healing. J Thromb Haemost 2006; 4: 932-939
  • 26 Leitner GC, Gruber R, Neumuller J, Wagner A, Kloimstein P, Hocker P, Kormoczi GF, Buchta C. Platelet content and growth factor release in platelet-rich plasma: a comparison of four different systems. Vox Sang 2006; 91: 135-139
  • 27 Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 2002; 84-A: 1032-1044
  • 28 Man D, Plosker H, Winland-Brown JE. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery. Plast Reconstr Surg 2001; 107: 229-237; discussion 229–238
  • 29 Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP?. Implant Dent 2001; 10: 225-228
  • 30 Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004; 62: 489-496
  • 31 Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85: 638-646
  • 32 Moojen DJ, Everts PA, Schure RM, Overdevest EP, van Zundert A, Knape JT, Castelein RM, Creemers LB, Dhert WJ. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res 2008; 26: 404-410
  • 33 Murphy S, Kahn RA, Holme S, Phillips GL, Sherwood W, Davisson W, Buchholz DH. Improved storage of platelets for transfusion in a new container. Blood 1982; 60: 194-200
  • 34 Nikolidakis D, Jansen JA. The biology of platelet-rich plasma and its application in oral surgery: literature review. Tissue Eng Part B Rev 2008; 14: 249-258
  • 35 Paderni S, Terzi S, Amendola L. Major bone defect treatment with an osteoconductive bone substitute. Musculoskelet Surg 2009; 93: 89-96
  • 36 Pallua N, Wolter T, Markowicz M. Platelet-rich plasma in burns. Burns 2010; 36: 4-8
  • 37 Peerbooms JC, de Wolf GS, Colaris JW, Bruijn DJ, Verhaar JA. No positive effect of autologous platelet gel after total knee arthroplasty. Acta Orthop 2009; 80: 557-562
  • 38 Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med 2010; 38: 255-262
  • 39 Rodriguez-Flores J, Palomar-Gallego MA, Enguita-Valls AB, Rodriguez-Peralto JL, Torres J. Influence of platelet-rich plasma on the histologic cCharacteristics of the autologous fat graft to the upper Lip of rabbits. Aesthetic Plast Surg 2010; DOI: 10.1007/s00266-010-9640-5.
  • 40 Rozman P, Bolta Z. Use of platelet growth factors in treating wounds and soft-tissue injuries. Acta Dermatovenerol Alp Panonica Adriat 2007; 16: 156-165
  • 41 Shah U, Ma AD. Tests of platelet function. Curr Opin Hematol 2007; 14: 432-437
  • 42 Shen YX, Fan ZH, Zhao JG, Zhang P. The application of platelet-rich plasma may be a novel treatment for central nervous system diseases. Med Hypotheses 2009; 73: 1038-1040
  • 43 Stammers AH, Trowbridge CC, Murdock JD, Yen BR, Klayman MH, Hess WF, Woods EL, Andreychik DA. Establishment of a Quality Control Program for Platelet Gel Preparation: A Comparison of Four Commercial Devices. Presented at the Society of Cardiovascular Anesthesiologists Meeting: 9th Annual Update on Cardiopulmonary Bypass. March 14–19, 2004, Snowmass, CO; 2004
  • 44 Sun Y, Feng Y, Zhang CQ, Chen SB, Cheng XG. The regenerative effect of platelet-rich plasma on healing in large osteochondral defects. Int Orthop 2010; 34: 589-597
  • 45 Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002; 70: 6524-6533
  • 46 Villela DL, Santos VL. Evidence on the use of platelet-rich plasma for diabetic ulcer: a systematic review. Growth Factors 2010; 28: 111-116
  • 47 Weibrich G, Hansen T, Kleis W, Buch R, Hitzler WE. Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone 2004; 34: 665-671
  • 48 Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002; 62: 343-350
  • 49 Wright-Carpenter T, Klein P, Schaferhoff P, Appell HJ, Mir LM, Wehling P. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. Int J Sports Med 2004; 25: 588-593
  • 50 Wright-Carpenter T, Opolon P, Appell HJ, Meijer H, Wehling P, Mir LM. Treatment of muscle injuries by local administration of autologous conditioned serum: animal experiments using a muscle contusion model. Int J Sports Med 2004; 25: 582-587